The latest featured news from Pituitary World News
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
In what he calls his passion in an ever-evolving field, world renowned neurosurgeon, Dr. Sandeep Kunwar presents a rational approach for the management of Craniopharyngiomas. He focuses on all aspects of this procedure.
From Lewis S. Blevins Jr., M.D. cofounder – Lehrer and others published a nice review on the role of stereotactic radiosurgery (SRS) for functioning and nonfunctioning pituitary adenomas. They reviewed several studies focusing on both the beneficial and adverse effects of the treatment of different tumor subtypes.